Vaginal DHEA, brand name prasterone, is a nightly insert that is FDA-approved for moderate-to-severe painful sex due to menopause.

Unlike vaginal estrogen, the tissue itself converts the DHEA locally into both estrogens and androgens, a process called intracrinology, which is why some clinicians consider it the only FDA-approved vaginal product that actually contains an androgen component. In its pivotal trial of 482 women, 12 weeks of prasterone improved all four measured outcomes versus placebo: cell changes, vaginal pH, and pain with sex, with vaginal discharge as the main side effect in about 6% of users. As with vaginal estrogen, blood hormone levels stayed within the normal postmenopausal range in the trial, and no progestogen is required alongside it, though endometrial safety hasn't been studied in trials longer than one year.

What to know about this answer

Vaginal DHEA's efficacy against placebo is well established by its pivotal trial. What's not settled is how it compares directly to vaginal estrogen, since no head-to-head trial exists, so the clinical preference some experts have for DHEA in severe pain is experience-based rather than data-based.

What the research shows, and which source each finding rests on

Prasterone (6.5 mg intravaginal DHEA nightly) is FDA-approved for moderate-to-severe dyspareunia due to menopause; in a phase III RCT of 482 women, 12 weeks of treatment improved all four FDA co-primary endpoints versus placebo (parabasal cells, superficial cells, vaginal pH, pain with sexual activity); the main side effect was vaginal discharge in about 6%; serum steroid levels remained within the normal postmenopausal range.

B[1]

No progestogen is needed with vaginal DHEA, with the caveat that endometrial safety has not been studied in trials beyond one year.

A[2]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

DHEA may work better for severe pain because of its androgen component

Rachel Rubin, MD, clinical practice

Rubin reports switching women who still have pain or UTIs on vaginal estrogen to nightly prasterone and seeing improvement, reasoning that the androgen component adds something estrogen alone does not, but this is clinical experience and mechanistic reasoning, not head-to-head trial data.

What would settle it: A randomized head-to-head trial of vaginal DHEA versus vaginal estrogen, with pain and infection endpoints, would clarify whether one truly outperforms the other or whether response is simply individual.

What is really going on here

  1. Which formulation fits my life - cream, insert, ring or DHEA?

Questions for your doctor

  1. Would vaginal DHEA be a reasonable option for me, especially if I've had a partial response to estrogen?
  2. What does it cost, and is prior authorization likely to be needed?
  3. How does the discharge side effect typically compare with other formulations?
  4. Is there a reason to prefer estrogen over DHEA in my specific situation?

Questions with no answer yet

Does vaginal DHEA actually outperform vaginal estrogen for severe pain specifically because of its androgen component, or would any effective local hormone product work just as well for the women who happen to be switched to it?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No head-to-head trial of vaginal DHEA versus vaginal estrogen exists, and the clinical preference for DHEA in severe pain is experience-based reasoning about the androgen component, not data-based.

What would test it: A randomized head-to-head trial of vaginal DHEA versus vaginal estrogen, with pain and infection endpoints as the primary outcomes.

Since endometrial safety for vaginal DHEA has not been studied beyond one year, is longer-term use, which is likely given the condition it treats is chronic, actually as safe as the one-year trial data suggest, or is this simply an untested question rather than a settled one?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No progestogen is needed alongside vaginal DHEA, with the explicit caveat that endometrial safety has not been studied in trials beyond one year, while real-world use typically extends well past the tested window because the underlying condition is lifelong.

What would test it: Longer-term endometrial safety surveillance, either registry data or an extended trial, covering years rather than the one-year window currently studied.

Does the local conversion of DHEA into both estrogens and androgens in the vaginal tissue mean the balance of that conversion differs meaningfully between individual women, and if so, does that explain why some women respond better to DHEA than to estrogen alone?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The mechanism of local conversion is described as the basis for DHEA containing an androgen component, without research measuring whether the ratio of that local conversion varies between women or predicts differential response.

What would test it: Tissue-level studies measuring individual variation in local DHEA-to-hormone conversion and testing whether that variation predicts symptom response.

Sources

  1. 1.Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.Labrie F, et al. Efficacy of intravaginal DHEA on moderate to severe dyspareunia and vaginal dryness. Menopause 2016;23(3):243-56 · Randomised trial
  2. 2.The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The 2020 GSM position statement of The North American Menopause Society, Menopause 2020;27(9):976-992 · Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides